BioPharma Resources

Drug Trial Radar · NCT03624322

Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101

Phase1 Randomized, Double-Blind, Placebo/Active-Controlled, SAD, 2-Way, Incomplete Block, 2-Period Crossover, Safety, Tolerability, PK/PD Study of 3 Doses INP105 (Olanzapine Delivered by I231 POD® Device) Nasal Spray in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Oct 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Aug 5, 2018

Primary completion

Oct 3, 2018

Study completion Oct 3, 2018

Sponsor

Lead sponsor
Impel PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Aug 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INP105, which is an investigational drug-device combination product comprised of the drug component OLZ administered by a Precision Olfactory Delivery (POD®) nasal spray device (I231 POD® Device). The proposed indication for INP105 is the treatment of acute agitation associated with schizophrenia and bipolar I disorder.

Conditions

  • Acute Agitation

Interventions

  • Zyprexa IMDrug

    5mg

  • ZydisDrug

    10mg orally disintegrating wafer

  • INP105Drug

    Single, ascending doses of 5, 10, or 20mg capsules OLZ (olanzapine) or placebo (MCC)

  • I231 POD® DeviceDevice

    Precision Olfactory Delivery (POD) device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: 30 days
  2. PK profile of OLZ INP105 TmaxTime frame: 72 hours
  3. PK profile of OLZ INP105 CmaxTime frame: 72 hours
  4. PK profile of Zyprexa IM TmaxTime frame: 72 hours
  5. PK profile of Zyprexa IM CmaxTime frame: 72 hrs
  6. PK profile of Zyprexa Zydis TmaxTime frame: 72 hours
  7. PK profile of Zyprexa Zydis CmaxTime frame: 72 hours
  8. PD effects of INP105 vs placeboTime frame: 72 hours
  9. PD effects of Zyprexa IMTime frame: 72 hours
  10. PD effects of Zyprexa ZydisTime frame: 72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Pty Ltd

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.